Transforming oncology clinical development

Publish date:

Alliance with Novo Oncology Associates facilitates collaboration Potential rewards from oncology drug development are high, but costs and risks are increasing. Factors include the trend towards targeted therapies, complexity of establishing acceptable endpoints, use of combination therapies and pressures from payers and patients.  Pharma companies can manage costs and risks better by measures like improving […]

Alliance with Novo Oncology Associates facilitates collaboration

Potential rewards from oncology drug development are high, but costs and risks are increasing. Factors include the trend towards targeted therapies, complexity of establishing acceptable endpoints, use of combination therapies and pressures from payers and patients. 

Pharma companies can manage costs and risks better by measures like improving the way they make strategic decisions and using intermediate endpoints. Above all, they need to collaborate with stakeholders such as regulators, payers and patient groups. Novo Oncology Associates (NOA) and Capgemini Consulting have set up an alliance to facilitate these initiatives.

Transforming_oncology_c...

File size: 3.12 MB File type: PDF

Related Resources

The secret to scaling Artificial Intelligence

Tune in to our podcast for a glimpse into where AI is today and how far it might take us...

Balance by Design

Among this time of disruption and discontinuity, ‘Balance by design’ aims to help...

We Collaborate

It’s time to tap into the phenomenal power of the collaborative Technology Business, even as...